In view of current clinical developments of potent STAT3 and Mcl-1 inhibitors, a combination of conventional treatments with these inhibitors might thus constitute a new therapeutic strategy in CLL. Here, STAT3 is linked to B-cell chronic lymphocytic leukemia.